AI Article Synopsis
- * This condition enables specific therapies, such as metastasis-directed therapy (MDT), which focuses on eradicating limited metastases while delaying more aggressive systemic treatments.
- * The review examines evidence for different MDTs, including radiotherapy for low-volume metastasis and the use of PSMA ligands, and highlights the need for further research on this evolving disease state.
Article Abstract
Oligometastatic prostate cancer is an evolving clinical entity as more data from novel imaging tools such as PSMA PET/CT emerges. Recognition of this disease entity allows for unique interventions which differ from conventional treatment of metastatic prostate cancers such as the initiation of chemotherapy. With metastasis-directed therapy (MDT), there is potential for early eradication of limited disease metastases and a delay in systemic treatment with its associated treatment-related toxicities. This review explores the current evidence and outcomes of different metastasis-directed therapies such as the role of radiotherapy in low volume metastasis and the use of PSMA ligands to facilitate pelvic lymph node dissections. With a deeper understanding of this low metastasis state, it has revolutionized the current viable treatment options, and more studies are ongoing to provide further insights into this unique disease entity.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10706851 | PMC |
| http://dx.doi.org/10.3390/jcm12237198 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Development and Validation of an MRI-Based Radiomics Nomogram to Predict the Prognosis of De Novo Oligometastatic Prostate Cancer Patients.
Cancer Med
December 2024
Department of Urology, The First Affiliated Hospital, Fujian Medical University, Fuzhou, China.
Objective: We aimed to develop and validate a nomogram based on MRI radiomics to predict overall survival (OS) for patients with de novo oligometastatic prostate cancer (PCa).
Methods: A total of 165 patients with de novo oligometastatic PCa were included in the study (training cohort, n = 115; validating cohort, n = 50). Among them, MRI scans were conducted and T2-weighted imaging (T2WI) and apparent diffusion coefficient (ADC) sequences were collected for radiomics features along with their clinicopathological features.
Results of a single arm phase II clinical trial: online-adaptive stereotactic body radiotherapy of abdominal-pelvic oligometastases.
Int J Radiat Oncol Biol Phys
December 2024
Department of Radiotherapy, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
Purpose: This study reports on the clinical outcomes of the single arm phase-II STEAL trial investigating online adaptive stereotactic body radiotherapy (SBRT) for abdominal-pelvic lymph node (A-P LN) oligometastases.
Methods: Patients with oligometastatic A-P LN were enrolled and treated to a total dose of 45 Gy in five fractions on the CyberKnife. For each patient, a library of three plans was created using a pre-treatment diagnostic CT scan and the treatment planning CT scan.
Stereotactic body radiotherapy as metastasis-directed therapy in oligometastatic prostate cancer: a systematic review and meta-analysis of randomized controlled trials.
Radiat Oncol
December 2024
Division of Oncology, Department of Clinical Sciences, Faculty of Medicine, Lund University, Lund, Sweden.
Background: The use of stereotactic body radiotherapy (SBRT) to definitively treat oligometastases in prostate cancer has drawn large clinical and research interests within radiation oncology. However, the evidence is considered in its early stages and there is currently no systematic review of randomized controlled trials (RCTs) in this field. We aimed to evaluate the efficacy and safety of SBRT as metastasis-directed therapy (MDT) in oligometastatic prostate cancer (OMPC) compared to no MDT reported in RCTs.
View Article and Find Full Text PDFThe quantitative impact of prostate-specific membrane antigen (PSMA) PET/CT staging in newly diagnosed metastatic prostate cancer and treatment-decision implications.
BJR Open
January 2024
Division of Radiotherapy and Imaging, Institute of Cancer Research, London, SW3 6JB, United Kingdom.
Article Synopsis
Prostatectomy and other local treatments for oligometastatic prostate cancer: recent and ongoing trials.
Curr Opin Urol
November 2024
Department of Urology.
Article Synopsis
- Oligometastatic prostate cancer (OMPCa) is an intermediate stage of cancer between localized and widespread disease, traditionally treated with androgen deprivation therapy (ADT) but now also considered for local therapies like cytoreductive prostatectomy (CRP) and radiotherapy.
- Recent studies suggest that CRP may be beneficial for some OMPCa patients, and ongoing trials are exploring its safety and effectiveness, alongside findings supporting the use of radiotherapy and ADT.
- There is still limited evidence for focal therapies and cryotherapy, highlighting the need for more clinical trials to better understand treatment options and suitability for patients with OMPCa.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!